Publications

Prostate Cancer after Initial High-Grade Prostatic Intraepithelial Neoplasia and Benign Prostate Biopsy

Can J Urol. 2015 Dec;22(6):8056-62.

Patel P, Nayak JG, Biljetina Z, Donnelly B, Trpkov K.

Abstract

INTRODUCTION:

Limited data exist on long term pathological outcomes in patients with initial prostate biopsies showing either high-grade intraepithelial neoplasia (HGPIN) or benign findings, who are subsequently diagnosed with prostate cancer.

MATERIALS AND METHODS:

Preoperative characteristics of patients showing either HGPIN or benign initial prostate biopsies were investigated and compared in patients with and without a subsequent diagnosis of prostate cancer. We also compared the biopsy and prostatectomy findings in patients with prostate cancer in both groups.

RESULTS:

We evaluated 161 and 85 patients with initial HGPIN and benign prostate biopsies, respectively, who underwent a subsequent biopsy. After a median follow up of 11 years, prostate cancer was detected in 26.7% patients after HGPIN and in 22.3% patients after initial benign biopsy. Ninety-eight percent of positive biopsies after initial HGPIN demonstrated either Gleason score (GS) 3 + 3 (86%) or GS 3 + 4 (12%). In the benign group, 100% of patients demonstrated prostate cancer on biopsy with either GS 3 + 3 (58%) or GS 3 + 4 (42%). Of 35 patients who underwent prostatectomy (22 after initial HGPIN biopsy and 13 after initial benign biopsy), all had node negative, organ-confined disease; 86% and 54% patients had GS6 disease, with = 5% tumor volume found in 91% and 62% of the HGPIN and benign group, respectively.

CONCLUSIONS:

Patients with initial HGPIN or benign biopsies preceding a diagnosis of prostate cancer usually show favourable pathology on positive biopsy and prostatectomy, most commonly exhibiting low volume and low grade disease. These findings may help clinicians risk-stratify patients who may benefit from conservative management options.

PubMed

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Lifestyle Management Program in Alberta – TrueNTH

The TrueNTH (pronounced True North) Lifestyle Management (LM) Program is part of the Global TrueNTH network funded by Movember (in partnership with Prostate Cancer Canada nationally). TrueNTH LM aims to improve the survivorship experience for men living with prostate cancer through physical activity, nutrition, and stress-reduction resources (programs and educational materials).

TrueNTH LM includes a free 12-week physical activity and yoga program with classes designed specifically to address the health and treatment related concerns for men living with prostate cancer. Men can also access a comprehensive online portal with tools, education, and home-based programming for help with staying active, reducing stress, and maintaining a proper diet.

In Calgary, TrueNTH LM has partnered with City of Calgary Recreation to offer programs at four different locations throughout the city. Registration is ongoing for men. In Edmonton, the Cancer Rehabilitation Clinic at the University of Alberta will be hosting a TrueNTH LM program starting in January 2016. Future programs will be announced as they become available. Men living in rural Alberta are able to join an online-based program at lifestyle.truenth.ca

All men who have been previously diagnosed with prostate cancer regardless of when they were diagnosed or what treatment they received can join the TrueNTH LM online portal or join a community program. Each person will undergo an initial health screening to ensure physical activity is safe.

For more information or to register, phone the Health and Wellness Lab in Calgary at .

Letter for participants

- Nicole Culos-Reed

Our International Network of Partners

Meeting these ambitious goals will not be possible without the committed engagement of our many partners across Alberta, Canada and the World. Learn more about our Partners.